Macrophage States in Cardiac Remodeling: Mechanisms, Clinical Implications, and Emerging Therapeutic Insights

Abstract

Cardiac remodeling, a complex adaptive process occurring in response to myocardial injury or stress, is critically orchestrated by immune cell dynamics, with macrophages playing central roles. Recent advances in immunology and single-cell transcriptomics have unveiled diverse macrophage states with distinct functional properties during cardiac remodeling. This article provides an in-depth review of the spectrum of macrophage phenotypes implicated in cardiac remodeling, elucidates their interplay with myocardial healing and dysfunction, and discusses the clinical and translational relevance of targeting macrophage polarization as a therapeutic strategy. Contemporary evidence from experimental and clinical studies is integrated to inform best practices and future research directions for clinicians and scientists.

Introduction

Cardiac remodeling refers to the structural and functional changes of the myocardium following injury such as myocardial infarction (MI), heart failure, or chronic pressure overload. This process is characterized by cellular hypertrophy, interstitial fibrosis, and alterations in the extracellular matrix. The immune response, particularly the role of macrophages, is now recognized as a pivotal determinant of both adaptive and maladaptive remodeling outcomes. Macrophages exhibit remarkable phenotypic plasticity, transitioning between pro-inflammatory and reparative states, which influences the trajectory of myocardial recovery or progression to heart failure. Understanding the dynamic states of macrophages, their molecular drivers, and their impact on cardiac structure and function is essential for advancing clinical management and developing novel therapeutic approaches.

Epidemiology / Disease Burden

Cardiac remodeling underlies the pathogenesis of numerous cardiovascular conditions, notably ischemic heart disease and heart failure, which remain leading causes of morbidity and mortality worldwide. The burden of heart failure is escalating, with over 64 million people affected globally and a five-year mortality rate exceeding 50% in advanced cases. The prevalence of pathological cardiac remodeling is closely linked to the incidence of acute MI, hypertension, and valvular diseases, especially in aging populations. Despite significant therapeutic advances, the high recurrence rates and chronicity of adverse remodeling highlight the need for new interventions targeting its immunological underpinnings.

Pathophysiology

Macrophages contribute both to the initiation and resolution of cardiac injury through their highly plastic phenotypic states. Traditionally, macrophages are categorized into classically activated (M1, pro-inflammatory) and alternatively activated (M2, anti-inflammatory/reparative) subsets, though in vivo states are more complex and dynamic. Immediately after injury, resident and infiltrating monocyte-derived macrophages adopt a pro-inflammatory M1-like phenotype, secreting cytokines (e.g., TNF-α, IL-1β) and matrix metalloproteinases to clear necrotic debris. As healing progresses, a phenotypic shift toward M2-like macrophages occurs, promoting angiogenesis, fibroblast activation, and extracellular matrix remodeling via secretion of IL-10, TGF-β, and growth factors. Recent single-cell RNA-sequencing studies have delineated further macrophage subpopulations with unique gene signatures and functions, including subsets involved in electrical conduction and tissue homeostasis. Dysregulation of macrophage transitions, persistence of pro-inflammatory phenotypes, or insufficient reparative activity exacerbates adverse remodeling and impairs functional recovery.

Risk Factors

Risk factors for adverse cardiac remodeling involving pathological macrophage responses include advanced age, diabetes mellitus, chronic kidney disease, persistent hypertension, and genetic predisposition. Notably, comorbid conditions such as obesity and metabolic syndrome promote chronic low-grade inflammation and alter macrophage polarization toward pro-inflammatory states. Repeated ischemic insults, impaired resolution of inflammation, and inadequate clearance of cellular debris further contribute to maladaptive remodeling. Recent data also implicate defective efferocytosis and impaired tissue-resident macrophage renewal as risk factors for persistent myocardial inflammation and fibrosis.

Clinical Features

Clinically, cardiac remodeling manifests as progressive changes in ventricular size, shape, and function. Patients may present with signs and symptoms of heart failure: dyspnea, exercise intolerance, fatigue, and peripheral edema. Electrocardiographic and echocardiographic changes include ventricular dilation, reduced ejection fraction, wall thinning, and diastolic dysfunction. Biomarkers such as NT-proBNP and cardiac troponins may reflect ongoing myocardial stress and injury. Importantly, the inflammatory milieu mediated by macrophage states is increasingly recognized as a driver of persistent symptoms and poor prognosis.

Diagnosis

Diagnosis of cardiac remodeling with immune involvement relies on a combination of imaging, biomarker assessment, and, in research settings, tissue characterization. Echocardiography and cardiac MRI provide detailed evaluation of ventricular geometry, function, and fibrosis. Emerging molecular imaging modalities targeting macrophage activation (e.g., PET tracers for TSPO or mannose receptor) offer non-invasive assessment of inflammatory activity. Circulating markers such as soluble CD163 and monocyte subsets may reflect ongoing macrophage-driven inflammation. Endomyocardial biopsy, though invasive, can directly assess macrophage infiltration and polarization, providing mechanistic insights in select cases.

Treatment & Management

Current management of cardiac remodeling focuses on mitigating underlying etiologies, optimizing neurohormonal blockade (ACE inhibitors, ARBs, beta-blockers, mineralocorticoid antagonists), and managing comorbidities. Emerging evidence supports the therapeutic potential of modulating macrophage phenotypes to enhance reparative processes and limit maladaptive remodeling. Strategies include promoting M2 polarization, enhancing efferocytosis, and targeting specific inflammatory pathways (e.g., IL-1β blockade with canakinumab or NLRP3 inhibitors). Cardiac rehabilitation, metabolic control, and device therapies (e.g., CRT, ICDs) remain integral to comprehensive care, with personalized approaches increasingly informed by immunophenotyping.

Recent Advances / Emerging Therapies

Recent advances in single-cell technologies have identified novel macrophage subsets and transcriptional programs relevant to cardiac remodeling. Therapeutic approaches under investigation include nanoparticle-mediated delivery of agents to modulate macrophage polarization, gene editing technologies (e.g., CRISPR) to alter macrophage function, and biologics targeting key inflammatory mediators. Preclinical studies have shown promise for agents that enhance reparative macrophage activity or selectively deplete pro-inflammatory subsets to improve cardiac healing. Clinical trials evaluating anti-inflammatory therapies, such as colchicine and IL-6 antagonists, are ongoing, with preliminary data suggesting benefits in selected populations. Integration of omics-based biomarkers and systems immunology approaches may enable precision immunomodulation in the near future.

Guideline Recommendations

While current heart failure and post-MI guidelines emphasize neurohormonal and hemodynamic optimization, recognition of the immune system's role in cardiac remodeling is growing. Expert consensus statements highlight the need for further research and clinical trials evaluating immunomodulatory therapies, particularly those targeting macrophage polarization and inflammatory pathways. Multidisciplinary care teams should consider enrolling eligible patients in clinical studies and adopt a personalized approach leveraging emerging biomarkers of immune activation. Ongoing updates to guidelines are anticipated as evidence for immune-targeted therapies matures.

Conclusion

Macrophage states represent a central axis in the pathophysiology of cardiac remodeling, mediating the balance between injury and repair. Advances in our understanding of macrophage heterogeneity, mechanisms of action, and clinical significance open new frontiers for diagnostic and therapeutic innovation. Translating these insights into effective, targeted therapies holds promise for improving outcomes in patients with myocardial injury and heart failure. Continued interdisciplinary research and integration of immunological biomarkers into clinical practice are essential for the evolution of precision cardiovascular medicine.